{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T02:14:26Z","timestamp":1772763266581,"version":"3.50.1"},"reference-count":83,"publisher":"Bentham Science Publishers Ltd.","issue":"6","funder":[{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico, Brazil","doi-asserted-by":"publisher","award":["305382\/2018-7"],"award-info":[{"award-number":["305382\/2018-7"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004901","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa de Minas Gerais, Brazil","doi-asserted-by":"publisher","award":["APQ-00801-16"],"award-info":[{"award-number":["APQ-00801-16"]}],"id":[{"id":"10.13039\/501100004901","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["PPL"],"published-print":{"date-parts":[[2020,6,9]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p>Huntington\u2019s Disease (HD) is an autosomal dominant, progressive neurodegenerative\ndisorder characterized by severe symptoms, including motor impairment, cognitive decline, and\npsychiatric alterations. Several systems, molecules, and mediators have been associated with the\npathophysiology of HD. Among these, there is the Renin-Angiotensin System (RAS), a peptide\nhormone system that has been associated with the pathology of neuropsychiatric and\nneurodegenerative disorders. Important alterations in this system have been demonstrated in HD.\nHowever, the role of RAS components in HD is still unclear and needs further investigation.\nNonetheless, modulation of the RAS components may represent a potential therapeutic strategy for\nthe treatment of HD.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0929866527666200110154523","type":"journal-article","created":{"date-parts":[[2020,1,14]],"date-time":"2020-01-14T13:16:15Z","timestamp":1579007775000},"page":"456-462","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["The Renin-Angiotensin System in Huntington\u2019s Disease: Villain or Hero?"],"prefix":"10.2174","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1592-8376","authenticated-orcid":true,"given":"Thatiane C.G.","family":"Machado","sequence":"first","affiliation":[{"name":"Departamento de Morfologia - Instituto de Ci\u00eancias Biol\u00f3gicas, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5392-1266","authenticated-orcid":true,"given":"Cristina","family":"Guatimosim","sequence":"additional","affiliation":[{"name":"Departamento de Morfologia - Instituto de Ci\u00eancias Biol\u00f3gicas, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3678-118X","authenticated-orcid":true,"given":"Lucas M.","family":"Kangussu","sequence":"additional","affiliation":[{"name":"Departamento de Morfologia - Instituto de Ci\u00eancias Biol\u00f3gicas, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"15005","DOI":"10.1038\/nrdp.2015.5","volume":"1","author":"Bates G.P.","year":"2015","unstructured":"Bates G.P.; Dorsey R.; Gusella J.F.; Hayden M.R.; Kay C.; Leavitt B.R.; Nance M.; Ross C.A.; Scahill R.I.; Wetzel R.; Wild E.J.; Tabrizi S.J.; Huntington disease. Nat Rev Dis Primers 2015,1(1),15005","journal-title":"Nat Rev Dis Primers"},{"key":"ref=2","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2011.112","volume":"2","author":"Bano D.","year":"2011","unstructured":"Bano D.; Zanetti F.; Mende Y.; Nicotera P.; Neurodegenerative processes in Huntington\u2019s disease. Cell Death Dis 2011,2(11)","journal-title":"Cell Death Dis"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S1474-4422(10)70245-3","volume":"10","author":"Ross C.A.","year":"2011","unstructured":"Ross C.A.; Tabrizi S.J.; Huntington\u2019s disease: from molecular pathogenesis to clinical treatment. Lancet Neurol 2011,10(1),83-98","journal-title":"Lancet Neurol"},{"key":"ref=4","doi-asserted-by":"publisher","author":"Shao J.","unstructured":"Shao J.; Diamond M.I.; Polyglutamine diseases: Emerging\n\tconcepts in pathogenesis and therapy. Hum. Mol. Genet., 2007, 16\n\tSpec No. 2(R2), R115-R123.","DOI":"10.1093\/hmg\/ddm213"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1093\/brain\/awn025","volume":"131","author":"Rosas H.D.","year":"2008","unstructured":"Rosas H.D.; Salat D.H.; Lee S.Y.; Zaleta A.K.; Pappu V.; Fischl B.; Greve D.; Hevelone N.; Hersch S.M.; Cerebral cortex and the clinical expression of Huntington\u2019s disease: complexity and heterogeneity. Brain 2008,131(Pt 4),1057-1068","journal-title":"Brain"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1111\/j.1750-3639.2012.00629.x","volume":"23","author":"R\u00fcb U.","year":"2013","unstructured":"R\u00fcb U.; Hoche F.; Brunt E.R.; Heinsen H.; Seidel K.; Del Turco D.; Paulson H.L.; Bohl J.; von Gall C.; Vonsattel J.P.; Korf H.W.; den Dunnen W.F.; Degeneration of the cerebellum in Huntington\u2019s disease (HD): possible relevance for the clinical picture and potential gateway to pathological mechanisms of the disease process. Brain Pathol 2013,23(2),165-177","journal-title":"Brain Pathol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/ana.410260103","volume":"26","author":"Oyanagi K.","year":"1989","unstructured":"Oyanagi K.; Takeda S.; Takahashi H.; Ohama E.; Ikuta F.; A quantitative investigation of the substantia nigra in Huntington\u2019s disease. Ann Neurol 1989,26(1),13-19","journal-title":"Ann Neurol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.parkreldis.2013.05.005","volume":"19","author":"Kiferle L.","year":"2013","unstructured":"Kiferle L.; Mazzucchi S.; Unti E.; Pesaresi I.; Fabbri S.; Nicoletti V.; Volterrani D.; Cosottini M.; Bonuccelli U.; Ceravolo R.; Nigral involvement and nigrostriatal dysfunction in Huntington\u2019s disease: evidences from an MRI and SPECT study. Parkinsonism Relat Disord 2013,19(9),800-805","journal-title":"Parkinsonism Relat Disord"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/S0140-6736(07)60111-1","volume":"369","author":"Walker F.O.","year":"2007","unstructured":"Walker F.O.; Huntington\u2019s disease. Lancet 2007,369(9557),218-228","journal-title":"Lancet"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"331","DOI":"10.2217\/nmt-2016-0008","volume":"6","author":"Baig S.S.","year":"2016","unstructured":"Baig S.S.; Strong M.; Quarrell O.W.; The global prevalence of Huntington\u2019s disease: a systematic review and discussion. Neurodegener Dis Manag 2016,6(4),331-343","journal-title":"Neurodegener Dis Manag"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1159\/000443738","volume":"46","author":"Rawlins M.D.","year":"2016","unstructured":"Rawlins M.D.; Wexler N.S.; Wexler A.R.; Tabrizi S.J.; Douglas I.; Evans S.J.; Smeeth L.; The prevalence of Huntington\u2019s disease. Neuroepidemiology 2016,46(2),144-153","journal-title":"Neuroepidemiology"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s10038-007-0227-1","volume":"53","author":"Paradisi I.","year":"2008","unstructured":"Paradisi I.; Hern\u00e1ndez A.; Arias S.; Huntington disease mutation in Venezuela: age of onset, haplotype analyses and geographic aggregation. J Hum Genet 2008,53(2),127-135","journal-title":"J Hum Genet"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/ene.13413","volume":"25","author":"McColgan P.","year":"2018","unstructured":"McColgan P.; Tabrizi S.J.; Huntington\u2019s disease: a clinical review. Eur J Neurol 2018,25(1),24-34","journal-title":"Eur J Neurol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/S1474-4422(09)70178-4","volume":"8","author":"van der Burg J.M.M.","year":"2009","unstructured":"van der Burg J.M.M.; Bj\u00f6rkqvist M.; Brundin P.; Beyond the brain: widespread pathology in Huntington\u2019s disease. Lancet Neurol 2009,8(8),765-774","journal-title":"Lancet Neurol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1002\/mds.25864","volume":"29","author":"Papoutsi M.","year":"2014","unstructured":"Papoutsi M.; Labuschagne I.; Tabrizi S.J.; Stout J.C.; The cognitive burden in Huntington\u2019s disease: pathology, phenotype, and mechanisms of compensation. Mov Disord 2014,29(5),673-683","journal-title":"Mov Disord"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/nature05292","volume":"443","author":"Lin M.T.","year":"2006","unstructured":"Lin M.T.; Beal M.F.; Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006,443(7113),787-795","journal-title":"Nature"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3233\/JHD-160205","volume":"5","author":"Kumar A.","year":"2016","unstructured":"Kumar A.; Ratan R.R.; Oxidative stress and Huntington\u2019s disease: The good, the bad, and the ugly. J Huntingtons Dis 2016,5(3),217-237","journal-title":"J Huntingtons Dis"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.it.2015.04.007","volume":"36","author":"Crotti A.","year":"2015","unstructured":"Crotti A.; Glass C.K.; The choreography of neuroinflammation in Huntington\u2019s disease. Trends Immunol 2015,36(6),364-373","journal-title":"Trends Immunol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1523\/JNEUROSCI.4974-09.2010","volume":"30","author":"Ribeiro F.M.","year":"2010","unstructured":"Ribeiro F.M.; Paquet M.; Ferreira L.T.; Cregan T.; Swan P.; Cregan S.P.; Ferguson S.S.G.; Metabotropic glutamate receptor-mediated cell signaling pathways are altered in a mouse model of Huntington\u2019s disease. J Neurosci 2010,30(1),316-324","journal-title":"J Neurosci"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12035-010-8153-1","volume":"43","author":"Ribeiro F.M.","year":"2011","unstructured":"Ribeiro F.M.; Pires R.G.W.; Ferguson S.S.G.; Huntington\u2019s disease and Group I metabotropic glutamate receptors. Mol Neurobiol 2011,43(1),1-11","journal-title":"Mol Neurobiol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/j.1471-4159.1992.tb09283.x","volume":"58","author":"Garrett M.C.","year":"1992","unstructured":"Garrett M.C.; Soares-da-Silva P.; Increased cerebrospinal fluid dopamine and 3,4-dihydroxyphenylacetic acid levels in Huntington\u2019s disease: evidence for an overactive dopaminergic brain transmission. J Neurochem 1992,58(1),101-106","journal-title":"J Neurochem"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1002\/ana.410220318","volume":"22","author":"Kish S.J.","year":"1987","unstructured":"Kish S.J.; Shannak K.; Hornykiewicz O.; Elevated serotonin and reduced dopamine in subregionally divided Huntington\u2019s disease striatum. Ann Neurol 1987,22(3),386-389","journal-title":"Ann Neurol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3389\/fnins.2013.00114","volume":"7","author":"Chen J.Y.","year":"2013","unstructured":"Chen J.Y.; Wang E.A.; Cepeda C.; Levine M.S.; Dopamine imbalance in Huntington\u2019s disease: a mechanism for the lack of behavioral flexibility. Front Neurosci 2013,7,114","journal-title":"Front Neurosci"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/B978-0-444-63425-2.00010-6","volume":"211","author":"Cepeda C.","year":"2014","unstructured":"Cepeda C.; Murphy K.P.; Parent M.; Levine M.S.; The role of dopamine in Huntington\u2019s disease. Prog Brain Res 2014,211,235-254","journal-title":"Prog Brain Res"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1002\/ana.410020406","volume":"2","author":"Arregui A.","year":"1977","unstructured":"Arregui A.; Bennett J.P.; Bird E.D.; Yamamura H.I.; Iversen L.L.; Snyder S.H.; Huntington\u2019s chorea: selective depletion of activity of angiotensin coverting enzyme in the corpus striatum. Ann Neurol 1977,2(4),294-298","journal-title":"Ann Neurol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/0014-2999(78)90029-8","volume":"52","author":"Arregui A.","year":"1978","unstructured":"Arregui A.; Emson P.C.; Spokes E.G.; Angiotensin-converting enzyme in substantia nigra: reduction of activity in Huntington\u2019s disease and after intrastriatal kainic acid in rats. Eur J Pharmacol 1978,52(1),121-124","journal-title":"Eur J Pharmacol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1007\/BF01717829","volume":"65","author":"Schweisfurth H.","year":"1987","unstructured":"Schweisfurth H.; Schi\u00f6berg-Schiegnitz S.; Kuhn W.; Parusel B.; Angiotensin I.; Angiotensin I converting enzyme in cerebrospinal fluid of patients with neurological diseases. Klin Wochenschr 1987,65(20),955-958","journal-title":"Klin Wochenschr"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"108","DOI":"10.3389\/fendo.2017.00108","volume":"8","author":"De Mello W.C.","year":"2017","unstructured":"De Mello W.C.; Gerena Y.; Ayala-Pe\u00f1a S.; Angiotensins and Huntington\u2019s disease: A study on immortalized progenitor striatal cell lines. Front Endocrinol (Lausanne) 2017,8,108","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1152\/physrev.00036.2005","volume":"86","author":"Paul M.","year":"2006","unstructured":"Paul M.; Poyan Mehr A.; Kreutz R.; Physiology of local renin-angiotensin systems. Physiol Rev 2006,86(3),747-803","journal-title":"Physiol Rev"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1210\/en.2003-0150","volume":"144","author":"Lavoie J.L.","year":"2003","unstructured":"Lavoie J.L.; Sigmund C.D.; Minireview: overview of the renin-angiotensin system--an endocrine and paracrine system. Endocrinology 2003,144(6),2179-2183","journal-title":"Endocrinology"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s00441-006-0190-8","volume":"326","author":"von Bohlen und Halbach O.","year":"2006","unstructured":"von Bohlen und Halbach O.; Albrecht D.; The CNS renin-angiotensin system. Cell Tissue Res 2006,326(2),599-616","journal-title":"Cell Tissue Res"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"R804","DOI":"10.1152\/ajpregu.00222.2010","volume":"300","author":"Xu P.","year":"2011","unstructured":"Xu P.; Sriramula S.; Lazartigues E.; ACE2\/ANG-(1-7)\/Mas pathway in the brain: the axis of good. Am J Physiol Regul Integr Comp Physiol 2011,300(4),R804-R817","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1042\/CS20180189","volume":"132","author":"Gironacci M.M.","year":"2018","unstructured":"Gironacci M.M.; Vicario A.; Cerezo G.; Silva M.G.; The depressor axis of the renin-angiotensin system and brain disorders: a translational approach. Clin Sci (Lond) 2018,132(10),1021-1038","journal-title":"Clin Sci (Lond)"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.bbr.2013.09.003","volume":"257","author":"Kangussu L.M.","year":"2013","unstructured":"Kangussu L.M.; Almeida-Santos A.F.; Bader M.; Alenina N.; Fontes M.A.P.; Santos R.A.; Aguiar D.C.; Campagnole-Santos M.J.; Angiotensin-(1-7) attenuates the anxiety and depression-like behaviors in transgenic rats with low brain angiotensinogen. Behav Brain Res 2013,257,25-30","journal-title":"Behav Brain Res"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1042\/CS20160116","volume":"130","author":"Almeida-Santos A.F.","year":"2016","unstructured":"Almeida-Santos A.F.; Kangussu L.M.; Moreira F.A.; Santos R.A.S.; Aguiar D.C.; Campagnole-Santos M.J.; Anxiolytic- and antidepressant-like effects of angiotensin-(1-7) in hypertensive transgenic (mRen2)27 rats. Clin Sci (Lond) 2016,130(14),1247-1255","journal-title":"Clin Sci (Lond)"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.bbr.2017.05.026","volume":"331","author":"Kangussu L.M.","year":"2017","unstructured":"Kangussu L.M.; Almeida-Santos A.F.; Moreira F.A.; Fontes M.A.P.; Santos R.A.S.; Aguiar D.C.; Campagnole-Santos M.J.; Reduced anxiety-like behavior in transgenic rats with chronically overproduction of angiotensin-(1-7): Role of the Mas receptor. Behav Brain Res 2017,331,193-198","journal-title":"Behav Brain Res"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1007\/s12035-015-9260-9","volume":"53","author":"Jiang T.","year":"2016","unstructured":"Jiang T.; Zhang Y.D.; Zhou J.S.; Zhu X.C.; Tian Y.Y.; Zhao H.D.; Lu H.; Gao Q.; Tan L.; Yu J.T.; Angiotensin-(1-7) is reduced and inversely correlates with Tau hyperphosphorylation in animal models of Alzheimer\u2019s Disease. Mol Neurobiol 2016,53(4),2489-2497","journal-title":"Mol Neurobiol"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.tins.2009.07.006","volume":"32","author":"Kehoe P.G.","year":"2009","unstructured":"Kehoe P.G.; Miners S.; Love S.; Angiotensins in Alzheimer\u2019s disease - friend or foe? Trends Neurosci 2009,32(12),619-628","journal-title":"Trends Neurosci"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.1016\/j.febslet.2012.09.004","volume":"586","author":"Tian M.","year":"2012","unstructured":"Tian M.; Zhu D.; Xie W.; Shi J.; Central angiotensin II-induced Alzheimer-like tau phosphorylation in normal rat brains. FEBS Lett 2012,586(20),3737-3745","journal-title":"FEBS Lett"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1177\/1470320309347789","volume":"11","author":"Mertens B.","year":"2010","unstructured":"Mertens B.; Vanderheyden P.; Michotte Y.; Sarre S.; The role of the central renin-angiotensin system in Parkinson\u2019s disease. J Renin Angiotensin Aldosterone Syst 2010,11(1),49-56","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.jns.2016.07.031","volume":"368","author":"Rocha N.P.","year":"2016","unstructured":"Rocha N.P.; Scalzo P.L.; Barbosa I.G.; de Campos-Carli S.M.; Tavares L.D.; de Souza M.S.; Christo P.P.; Reis H.J.; Sim\u00f5es E Silva A.C.; Teixeira A.L.; Peripheral levels of angiotensins are associated with depressive symptoms in Parkinson\u2019s disease. J Neurol Sci 2016,368,235-239","journal-title":"J Neurol Sci"},{"key":"ref=42","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2013.07.016","author":"Dominguez-Meijide A.","unstructured":"Dominguez-Meijide A.; Villar-Cheda B.; Garrido-Gil P.; Sierrra-Paredes G.; Guerra M.J.; Labandeira-Garcia J.L.;  Effect of chronic treatment with angiotensin type 1 receptor antagonists on striatal dopamine levels in normal rats and in a rat model of Parkinson\u2019s disease treated with L-DOPA Neuropharmacology,\n\t2014, 76(Pt A), 156-168","journal-title":"Effect of chronic treatment with angiotensin type 1 receptor antagonists on striatal dopamine levels in normal rats and in a rat model of Parkinson\u2019s disease treated with L-DOPA Neuropharmacology,\n\t2014, 76(Pt A), 156-168"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1111\/j.1365-2796.2008.01981.x","volume":"264","author":"Fyhrquist F.","year":"2008","unstructured":"Fyhrquist F.; Saijonmaa O.; Renin-angiotensin system revisited. J Intern Med 2008,264(3),224-236","journal-title":"J Intern Med"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1161\/01.ATV.0000253889.09765.5f","volume":"27","author":"Jankowski V.","year":"2007","unstructured":"Jankowski V.; Vanholder R.; van der Giet M.; T\u00f6lle M.; Karadogan S.; Gobom J.; Furkert J.; Oksche A.; Krause E.; Tran T.N.; Tepel M.; Schuchardt M.; Schl\u00fcter H.; Wiedon A.; Beyermann M.; Bader M.; Todiras M.; Zidek W.; Jankowski J.; Mass-spectrometric identification of a novel angiotensin peptide in human plasma. Arterioscler Thromb Vasc Biol 2007,27(2),297-302","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1161\/CIRCRESAHA.113.301077","volume":"112","author":"Lautner R.Q.","year":"2013","unstructured":"Lautner R.Q.; Villela D.C.; Fraga-Silva R.A.; Silva N.; Verano-Braga T.; Costa-Fraga F.; Jankowski J.; Jankowski V.; Sousa F.; Alzamora A.; Soares E.; Barbosa C.; Kjeldsen F.; Oliveira A.; Braga J.; Savergnini S.; Maia G.; Peluso A.B.; Passos-Silva D.; Ferreira A.; Alves F.; Martins A.; Raizada M.; Paula R.; Motta-Santos D.; Klempin F.; Pimenta A.; Alenina N.; Sinisterra R.; Bader M.; Campagnole-Santos M.J.; Santos R.A.; Discovery and characterization of alamandine: a novel component of the renin-angiotensin system. Circ Res 2013,112(8),1104-1111","journal-title":"Circ Res"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"H958","DOI":"10.1152\/ajpheart.00723.2018","volume":"316","author":"Santos R.A.S.","year":"2019","unstructured":"Santos R.A.S.; Oudit G.Y.; Verano-Braga T.; Canta G.; Steckelings U.M.; Bader M.; The renin-angiotensin system: going beyond the classical paradigms. Am J Physiol Heart Circ Physiol 2019,316(5),H958-H970","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"8258","DOI":"10.1073\/pnas.1432869100","volume":"100","author":"Santos R.A.","year":"2003","unstructured":"Santos R.A.; Simoes e Silva A.C.; Maric C.; Silva D.M.; Machado R.P.; de Buhr I.; Heringer-Walther S.; Pinheiro S.V.; Lopes M.T.; Bader M.; Mendes E.P.; Lemos V.S.; Campagnole-Santos M.J.; Schultheiss H.P.; Speth R.; Walther T.; Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci USA 2003,100(14),8258-8263","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/0014-5793(94)01292-9","volume":"357","author":"Metzger R.","year":"1995","unstructured":"Metzger R.; Bader M.; Ludwig T.; Berberich C.; Bunnemann B.; Ganten D.; Expression of the mouse and rat mas proto-oncogene in the brain and peripheral tissues. FEBS Lett 1995,357(1),27-32","journal-title":"FEBS Lett"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1152\/physrev.00023.2016","volume":"98","author":"Santos R.A.S.","year":"2018","unstructured":"Santos R.A.S.; Sampaio W.O.; Alzamora A.C.; Motta-Santos D.; Alenina N.; Bader M.; Campagnole-Santos M.J.; The ACE2\/Angiotensin-(1-7)\/MAS axis of the renin-angiotensin system: Focus on angiotensin-(1-7). Physiol Rev 2018,98(1),505-553","journal-title":"Physiol Rev"},{"key":"ref=50","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0016037","volume":"6","author":"Zhu D.","year":"2011","unstructured":"Zhu D.; Shi J.; Zhang Y.; Wang B.; Liu W.; Chen Z.; Tong Q.; Central angiotensin II stimulation promotes \u03b2 amyloid production in Sprague Dawley rats. PLoS One 2011,6(1)","journal-title":"PLoS One"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"841","DOI":"10.2174\/0929866524666170822120258","volume":"24","author":"Almeida-Santos A.F.","year":"2017","unstructured":"Almeida-Santos A.F.; Kangussu L.M.; Campagnole-Santos M.J.; The renin-angiotensin system and the neurodegenerative diseases: A brief review. Protein Pept Lett 2017,24(9),841-853","journal-title":"Protein Pept Lett"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/s0196-9781(98)00044-8","volume":"19","author":"von Bohlen und Halbach O.","year":"1998","unstructured":"von Bohlen und Halbach O.; Albrecht D.; Angiotensin II inhibits long-term potentiation within the lateral nucleus of the amygdala through AT1 receptors. Peptides 1998,19(6),1031-1036","journal-title":"Peptides"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.neulet.2006.12.040","volume":"415","author":"Tchekalarova J.","year":"2007","unstructured":"Tchekalarova J.; Albrecht D.; Angiotensin I.I.; Angiotensin II suppresses long-term depression in the lateral amygdala of mice via L-type calcium channels. Neurosci Lett 2007,415(1),68-72","journal-title":"Neurosci Lett"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s00213-012-2913-8","volume":"226","author":"Tota S.","year":"2013","unstructured":"Tota S.; Goel R.; Pachauri S.D.; Rajasekar N.; Najmi A.K.; Hanif K.; Nath C.; Effect of angiotensin II on spatial memory, cerebral blood flow, cholinergic neurotransmission, and brain derived neurotrophic factor in rats. Psychopharmacology (Berl) 2013,226(2),357-369","journal-title":"Psychopharmacology (Berl)"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.mcn.2005.03.012","volume":"29","author":"Hellner K.","year":"2005","unstructured":"Hellner K.; Walther T.; Schubert M.; Albrecht D.; Angiotensin-(1-7) enhances LTP in the hippocampus through the G-protein-coupled receptor Mas. Mol Cell Neurosci 2005,29(3),427-435","journal-title":"Mol Cell Neurosci"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.nlm.2011.10.003","volume":"97","author":"Lazaroni T.L.","year":"2012","unstructured":"Lazaroni T.L.; Raslan A.C.S.; Fontes W.R.; de Oliveira M.L.; Bader M.; Alenina N.; Moraes M.F.; Dos Santos R.A.; Pereira G.S.; Angiotensin-(1-7)\/Mas axis integrity is required for the expression of object recognition memory. Neurobiol Learn Mem 2012,97(1),113-123","journal-title":"Neurobiol Learn Mem"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/0014-2999(95)00762-8","volume":"297","author":"Ge J.","year":"1996","unstructured":"Ge J.; Barnes N.M.; Alterations in angiotensin AT1 and AT2 receptor subtype levels in brain regions from patients with neurodegenerative disorders. Eur J Pharmacol 1996,297(3),299-306","journal-title":"Eur J Pharmacol"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fendo.2012.00164","volume":"164","author":"Guimond M.O.","year":"2012","unstructured":"Guimond M.O.; Gallo-Payet N.; How does angiotensin AT2 receptor activation help neuronal differentiation and improve neuronal pathological situations? Front Endocrinol 2012,164(3),1-12","journal-title":"Front Endocrinol"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.ntt.2014.11.004","volume":"47","author":"Lu J.","year":"2015","unstructured":"Lu J.; Wu L.; Jiang T.; Wang Y.; Zhao H.; Gao Q.; Pan Y.; Tian Y.; Zhang Y.; Angiotensin AT2 receptor stimulation inhibits activation of NADPH oxidase and ameliorates oxidative stress in rotenone model of Parkinson\u2019s disease in CATH.a cells. Neurotoxicol Teratol 2015,47,16-24","journal-title":"Neurotoxicol Teratol"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/S0006-8993(01)02100-X","volume":"897","author":"Kram\u00e1r E.A.","year":"2001","unstructured":"Kram\u00e1r E.A.; Armstrong D.L.; Ikeda S.; Wayner M.J.; Harding J.W.; Wright J.W.; The effects of angiotensin IV analogs on long-term potentiation within the CA1 region of the hippocampus in vitro. Brain Res 2001,897(1-2),114-121","journal-title":"Brain Res"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.neuroscience.2003.12.006","volume":"124","author":"Lee J.","year":"2004","unstructured":"Lee J.; Albiston A.L.; Allen A.M.; Mendelsohn F.A.; Ping S.E.; Barrett G.L.; Murphy M.; Morris M.J.; McDowall S.G.; Chai S.Y.; Effect of I.C.V. injection of AT4 receptor ligands, NLE1-angiotensin IV and LVV-hemorphin 7, on spatial learning in rats. Neuroscience 2004,124(2),341-349","journal-title":"Neuroscience"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1016\/j.peptides.2010.08.023","volume":"31","author":"Olson M.L.","year":"2010","unstructured":"Olson M.L.; Cero I.J.; Intrahippocampal Norleucine-Angiotensin IV mitigates scopolamine-induced spatial working memory deficits. Peptides 2010,31(12),2209-2215","journal-title":"Peptides"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.neuropharm.2013.01.025","volume":"70","author":"Paris J.J.","year":"2013","unstructured":"Paris J.J.; Eans S.O.; Mizrachi E.; Reilley K.J.; Ganno M.L.; McLaughlin J.P.; Central administration of angiotensin IV rapidly enhances novel object recognition among mice. Neuropharmacology 2013,70,247-253","journal-title":"Neuropharmacology"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1177\/1470320308099084","volume":"9","author":"Wright J.W.","year":"2008","unstructured":"Wright J.W.; Harding J.W.; The angiotensin AT4 receptor subtype as a target for the treatment of memory dysfunction associated with Alzheimer\u2019s disease. J Renin Angiotensin Aldosterone Syst 2008,9(4),226-237","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1111\/j.1460-9568.2010.07448.x","volume":"32","author":"Villar-Cheda B.","year":"2010","unstructured":"Villar-Cheda B.; Rodr\u00edguez-Pallares J.; Valenzuela R.; Mu\u00f1oz A.; Guerra M.J.; Baltatu O.C.; Labandeira-Garcia J.L.; Nigral and striatal regulation of angiotensin receptor expression by dopamine and angiotensin in rodents: implications for progression of Parkinson\u2019s disease. Eur J Neurosci 2010,32(10),1695-1706","journal-title":"Eur J Neurosci"},{"key":"ref=66","first-page":"67","volume":"8","author":"Labandeira-Garc\u00eda J.L.","year":"2014","unstructured":"Labandeira-Garc\u00eda J.L.; Garrido-Gil P.; Rodriguez-Pallares J.; Valenzuela R.; Borrajo A.; Rodr\u00edguez-Perez A.I.; Brain renin-angiotensin system and dopaminergic cell vulnerability. Front Neuroanat 2014,8,67","journal-title":"Front Neuroanat"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1111\/j.1476-5381.1996.tb15418.x","volume":"118","author":"Brown D.C.","year":"1996","unstructured":"Brown D.C.; Steward L.J.; Ge J.; Barnes N.M.; Ability of angiotensin II to modulate striatal dopamine release via the AT1 receptor in vitro and in vivo. Br J Pharmacol 1996,118(2),414-420","journal-title":"Br J Pharmacol"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"645","DOI":"10.3109\/10641969709083176","volume":"19","author":"Jenkins T.A.","year":"1997","unstructured":"Jenkins T.A.; Chai S.Y.; Mendelsohn F.A.O.; Effect of angiotensin II on striatal dopamine release in the spontaneous hypertensive rat. Clin Exp Hypertens 1997,19(5-6),645-658","journal-title":"Clin Exp Hypertens"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1111\/j.1460-9568.2005.04188.x","volume":"22","author":"Stragier B.","year":"2005","unstructured":"Stragier B.; Hristova I.; Sarre S.; Ebinger G.; Michotte Y.; \n                        In vivo characterization of the angiotensin-(1-7)-induced dopamine and \u03b3-aminobutyric acid release in the striatum of the rat. Eur J Neurosci 2005,22(3),658-664","journal-title":"Eur J Neurosci"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1046\/j.1471-4159.1997.68031304.x","volume":"68","author":"Jenkins T.A.","year":"1997","unstructured":"Jenkins T.A.; Mendelsohn F.A.O.; Chai S.Y.; Angiotensin-converting enzyme modulates dopamine turnover in the striatum. J Neurochem 1997,68(3),1304-1311","journal-title":"J Neurochem"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"4099","DOI":"10.1167\/iovs.11-9167","volume":"53","author":"Fujita T.","year":"2012","unstructured":"Fujita T.; Hirooka K.; Nakamura T.; Itano T.; Nishiyama A.; Nagai Y.; Shiraga F.; Neuroprotective effects of angiotensin II type 1 receptor (AT1-R) blocker via modulating AT1-R signaling and decreased extracellular glutamate levels. Invest Ophthalmol Vis Sci 2012,53(7),4099-4110","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/s12012-012-9184-9","volume":"13","author":"Qi J.","year":"2013","unstructured":"Qi J.; Zhang D.M.; Suo Y.P.; Song X.A.; Yu X.J.; Elks C.; Lin Y.X.; Xu Y.Y.; Zang W.J.; Zhu Z.; Kang Y.M.; Renin-angiotensin system modulates neurotransmitters in the paraventricular nucleus and contributes to angiotensin II-induced hypertensive response. Cardiovasc Toxicol 2013,13(1),48-54","journal-title":"Cardiovasc Toxicol"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1001\/jamaneurol.2014.3367","volume":"72","author":"Lin F.C.","year":"2015","unstructured":"Lin F.C.; Tsai C.P.; Kuang-Wu Lee J.; Wu M.T.; Tzu-Chi Lee C.; Angiotensin-converting enzyme inhibitors and amyotrophic lateral sclerosis risk: a total population-based case-control study. JAMA Neurol 2015,72(1),40-48","journal-title":"JAMA Neurol"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1093\/ajh\/hpu197","volume":"28","author":"Villapol S.","year":"2015","unstructured":"Villapol S.; Saavedra J.M.; Neuroprotective effects of angiotensin receptor blockers. Am J Hypertens 2015,28(3),289-299","journal-title":"Am J Hypertens"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1177\/1470320315583582","volume":"16","author":"Kalra J.","year":"2015","unstructured":"Kalra J.; Prakash A.; Kumar P.; Majeed A.B.A.; Cerebroprotective effects of RAS inhibitors: Beyond their cardio-renal actions. J Renin Angiotensin Aldosterone Syst 2015,16(3),459-468","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"5733","DOI":"10.1073\/pnas.85.15.5733","volume":"85","author":"Reiner A.","year":"1988","unstructured":"Reiner A.; Albin R.L.; Anderson K.D.; D\u2019Amato C.J.; Penney J.B.; Young A.B.; Differential loss of striatal projection neurons in Huntington disease. Proc Natl Acad Sci USA 1988,85(15),5733-5737","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.jchemneu.2004.02.005","volume":"27","author":"Deng Y.P.","year":"2004","unstructured":"Deng Y.P.; Albin R.L.; Penney J.B.; Young A.B.; Anderson K.D.; Reiner A.; Differential loss of striatal projection systems in Huntington\u2019s disease: a quantitative immunohistochemical study. J Chem Neuroanat 2004,27(3),143-164","journal-title":"J Chem Neuroanat"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1111\/j.1471-4159.1986.tb04539.x","volume":"47","author":"Butterworth J.","year":"1986","unstructured":"Butterworth J.; Changes in nine enzyme markers for neurons, glia, and endothelial cells in agonal state and Huntington\u2019s disease caudate nucleus. J Neurochem 1986,47(2),583-587","journal-title":"J Neurochem"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1159\/000093867","volume":"55","author":"Panegyres P.K.","year":"2006","unstructured":"Panegyres P.K.; Beilby J.; Bulsara M.; Toufexis K.; Wong C.; A study of potential interactive genetic factors in Huntington\u2019s disease. Eur Neurol 2006,55(4),189-192","journal-title":"Eur Neurol"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"878","DOI":"10.3390\/molecules15020878","volume":"15","author":"T\u00fanez I.","year":"2010","unstructured":"T\u00fanez I.; Tasset I.; P\u00e9rez-De La Cruz V.; Santamar\u00eda A.; 3-Nitropropionic acid as a tool to study the mechanisms involved in Huntington\u2019s disease: past, present and future. Molecules 2010,15(2),878-916","journal-title":"Molecules"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.neuro.2014.10.004","volume":"45","author":"Hariharan A.","year":"2014","unstructured":"Hariharan A.; Shetty S.; Shirole T.; Jagtap A.G.; Potential of protease inhibitor in 3-nitropropionic acid induced Huntington\u2019s disease like symptoms: mitochondrial dysfunction and neurodegeneration. Neurotoxicology 2014,45,139-148","journal-title":"Neurotoxicology"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/1750-1326-9-49","volume":"9","author":"Lee D.H.","year":"2014","unstructured":"Lee D.H.; Heidecke H.; Schr\u00f6der A.; Paul F.; Wachter R.; Hoffmann R.; Ellrichmann G.; Dragun D.; Waschbisch A.; Stegbauer J.; Klotz P.; Gold R.; Dechend R.; M\u00fcller D.N.; Saft C.; Linker R.A.; Increase of angiotensin II type 1 receptor auto-antibodies in Huntington\u2019s disease. Mol Neurodegener 2014,9(1),49","journal-title":"Mol Neurodegener"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"33861","DOI":"10.1038\/srep33861","volume":"6","author":"Imamura T.","year":"2016","unstructured":"Imamura T.; Fujita K.; Tagawa K.; Ikura T.; Chen X.; Homma H.; Tamura T.; Mao Y.; Taniguchi J.B.; Motoki K.; Nakabayashi M.; Ito N.; Yamada K.; Tomii K.; Okano H.; Kaye J.; Finkbeiner S.; Okazawa H.; Identification of hepta-histidine as a candidate drug for Huntington\u2019s disease by in silico-in vitro- in vivo-integrated screens of chemical libraries. Sci Rep 2016,6(1),33861","journal-title":"Sci Rep"}],"container-title":["Protein &amp; Peptide Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/178270","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,2]],"date-time":"2020-08-02T04:17:00Z","timestamp":1596341820000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/178270\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,9]]},"references-count":83,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6,9]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0929866527666200110154523","relation":{},"ISSN":["0929-8665"],"issn-type":[{"value":"0929-8665","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6,9]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-06-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-08-22","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-11-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}